FGEN FibroGen, Inc

27.25
+0.10  (0%)
Previous Close 27.15
Open 27.15
Price To book 13.28
Market Cap 1.91B
Shares 69,944,000
Volume 274,079
Short Ratio 6.49
Av. Daily Volume 480,295

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 3Q 2017.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 3 data from China trial released January 30, 2017. Primary endpoints met with China NDA to be filed 3Q 2017.
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 2 trial enrollment commenced January 2016. Continues to enroll as of November 2016.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Data due 3Q 2017.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
Pamrevlumab (FG-3019)
Pancreatic cancer